European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00217763|
Recruitment Status : Unknown
Verified December 2007 by Bellus Health Inc.
Recruitment status was: Active, not recruiting
First Posted : September 22, 2005
Last Update Posted : December 10, 2007
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease||Drug: 3APS||Phase 3|
- Duration of treatment: 18 months
- 3 treatment arms:
Placebo and 2 different doses of active drug.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||930 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase III Study of the Efficacy and Safety of 3APS as Add-on Therapy in Mild to Moderate Alzheimer's Disease|
|Study Start Date :||September 2005|
|Estimated Study Completion Date :||December 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00217763
Show 69 Study Locations
|Principal Investigator:||Pr. Bruno Vellas||University Hospital Center, Toulouse|